<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668028</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-114-18-01</org_study_id>
    <secondary_id>KCT0003174</secondary_id>
    <nct_id>NCT03668028</nct_id>
  </id_info>
  <brief_title>A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear</brief_title>
  <official_title>A Multi-center, Randomized, Independent Evaluator-Subject Blinded, Placebo-Controlled, Phase I/III Clinical Study to Evaluate Safety and Efficacy of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tego Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tego Science, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rotator cuff tear is one of the most common shoulder diseases and retears occure frequently
      after arthroscopic repair. Therefore, there is growing need of new therapy for improving
      structural outcome. This study evaluates the efficacy and safety of autologous fibroblasts
      during arthroscopic repair. The primary outcome is the retear rate after 24 weeks of
      arthroscopic repair with autologous fibroblasts. The secondary outcomes are functional
      evaluations including ROM, Constant score, ASES score and SST at 24 and 52 week.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retear rate</measure>
    <time_frame>24week</time_frame>
    <description>Retear rate assessed by independent evaluator with MRI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Rotator Cuff Injuries</condition>
  <arm_group>
    <arm_group_label>TPX-114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergo arthroscopic rotator cuff repair with TPX-114.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TPX-114</intervention_name>
    <description>Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.</description>
    <arm_group_label>TPX-114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroscopic surgery</intervention_name>
    <description>Subjects undergo conventional arthroscopic surgery for rotator cuff repair.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TPX-114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must

          1. be male or female, 19 years of age and older.

          2. require arthroscopic repair for full-thickness rotator cuff tear(＞2cm, ≤5cm) confirmed
             by MRI after 3 months of conservative management

          3. allow skin biopsy.

          4. be able and willing to give informed consent for participation in the trial

        Exclusion Criteria:

        Participants must not

          1. be inappropriate for skin biopsy.

          2. have subscapularis tear.

          3. have medical history of prior shoulder surgery, allergies to proteins of bovine
             origin, anaphylaxis to gentamicin, coagulopathy, genetic disorder related to
             fibroblasts or collagen (ex. achondroplasia, osteogenesis imperfecta) and malignant
             tumor within 5 years.

          4. have autoimmune disease including RA, positive HIV Ab result, acute trauma, chronic
             shoulder dislocation, pyogenic infection or scapulohumeral osteoarthritis at screening
             visit.

          5. be pregnant, state of breast feeding or disagree with the use of contraceptive method.

          6. require other surgical or nonsurgical procedures other than arthroscopic repair.

          7. have participated in other clinical trials and received investigational agents within
             4 weeks before participation of this study.

          8. be considered inappropriate for this study by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Han Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jikhyon Han</last_name>
    <phone>82)2-818-2900</phone>
    <email>jhhan@tegoscience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mighye Kang</last_name>
    <phone>82)2-818-2900</phone>
    <email>mhkang17@tegoscience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Han Oh, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sae Hoon Kim, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

